Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07358078 · ClinicalTrials.gov registry record
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
A clinical trial of Transthyretin Amyloidosis With Cardiomyopathy, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT07358078 is a study of Transthyretin Amyloidosis With Cardiomyopathy that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 2,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07358078, a study of Transthyretin Amyloidosis With Cardiomyopathy, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care
Conditions Studied
Study Locations (1)
New Jersey
- Clinical Trial Site - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2030-10-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07358078
The ClinicalTrials.gov registry entry for NCT07358078 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transthyretin Amyloidosis With Cardiomyopathy appearing as the primary indexed condition, and to 0 interventions.
NCT07358078 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT07358078 about?
NCT07358078 is a clinical study titled "DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting". The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in r...
What is the current status of trial NCT07358078?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2026-01-09. Estimated completion is 2030-10-23.
What conditions does trial NCT07358078 study?
This clinical trial studies the following conditions: Transthyretin Amyloidosis With Cardiomyopathy.
Who is sponsoring clinical trial NCT07358078?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07358078 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloidosis With Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.